TELA Bio (NASDAQ:TELA) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Key Points

• TELA Bio reported a quarterly earnings per share (EPS) of ($0.22), which missed the consensus estimate of ($0.18) by $0.04.
• The company has a market capitalization of $73.58 million and a negative return on equity of 402.45%.
• Wall Street Zen downgraded TELA Bio's stock rating from "hold" to "sell," amidst an average target price of $7.25.

TELA Bio (NASDAQ:TELA - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04), Zacks reports. TELA Bio had a negative net margin of 54.12% and a negative return on equity of 329.48%. The company had revenue of $20.20 million during the quarter, compared to the consensus estimate of $20.67 million. TELA Bio updated its FY 2025 guidance to EPS.

TELA Bio Price Performance

Shares of TELA traded down $0.03 during midday trading on Friday, hitting $1.58. 3,092 shares of the company traded hands, compared to its average volume of 177,466. The stock has a 50-day moving average of $1.86 and a 200-day moving average of $1.76. TELA Bio has a one year low of $0.86 and a one year high of $3.26. The firm has a market cap of $62.40 million, a P/E ratio of -1.41 and a beta of 0.93. The company has a debt-to-equity ratio of 4.14, a current ratio of 3.19 and a quick ratio of 3.40.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded shares of TELA Bio from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.